Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 9—September 2018
Dispatch

Use of Favipiravir to Treat Lassa Virus Infection in Macaques

Kyle Rosenke, Heinz FeldmannComments to Author , Jonna B. Westover, Patrick William Hanley, Cynthia Martellaro, Friederike Feldmann, Greg Saturday, Jamie Lovaglio, Dana P. Scott, Yousuke Furuta, Takashi Komeno, Brian B. Gowen, and David SafronetzComments to Author 
Author affiliations: National Institutes of Health, Hamilton, Montana, USA (K. Rosenke, H. Feldmann, P.W. Hanley, C. Martellaro, F. Feldmann, G. Saturday, J. Lovaglio, D.P. Scott); University of Manitoba, Winnipeg, Manitoba, Canada (H. Feldmann, D. Safronetz); Utah State University, Logan, Utah, USA (J.B. Westover, B.B. Gowen); Toyama Chemical Co., Ltd., Toyama, Japan (Y. Furuta, T. Komeno); Public Health Agency of Canada, Winnipeg (D. Safronetz)

Main Article

Table

Study design for treatment of Lassa virus infection in cynomolgus macaques*

Study, no. animals Treatment Frequency† Dose, mg/kg Loading dose, mg/kg Total daily dose, mg/kg Survived/total, no.
First
4 Placebo Every 24 h Volume equivalent Volume equivalent Volume equivalent 0/4
4
 Favipiravir
 Every 24 h
 300
 300
 300
 4/4
Second
4 Placebo Every 8 h Volume equivalent. Volume equivalent Volume equivalent 0/4
4 Favipiravir Every 8 h 50 300 150 0/4

*All animals were challenged with a previously determined lethal dose of 104 50% tissue culture infective dose of Lassa virus (strain Josiah) via intramuscular injection. At day 4 after infection, a time coinciding with the earliest onset of detectable viremia, treatment with placebo or drug was initiated by intravenous injection of the loading dose followed by daily (days 5–17) subcutaneous dosing. Animals were examined daily for clinical signs of disease, and samples were taken for hematologic, blood chemistry, and virologic analyses at 12 times throughout the study, beginning on the day of virus challenge and ending on day 56 after infection.
†For 14 d.

Main Article

Page created: August 15, 2018
Page updated: August 15, 2018
Page reviewed: August 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external